Delpor

Delpor, Inc. engages in developing and acquiring drug delivery technologies that enable the sustained or pattern specific release of proteins, peptides, and small molecules through a small non-mechanical subcutaneous implant. Its technologies include Prozor, which is used for the delivery of antipsychotics and other small molecule drugs from a non-mechanical implantable drug delivery device; NANOPOR, a non-mechanical implantable drug delivery device in which sustained release is provided by membrane architecture; and Delos PUMP, a self-contained and electro-osmotically driven implantable drug delivery device to deliver drugs in predetermined patterns. The company was incorporated in 2009 and is based in San Francisco, California.

Delpor headquartered in United States, North America, operates in the Biotechnology, Biopharma, Commercial sector. The company focuses on Biotechnology and has secured $292.2M in funding across 60 round(s). With a team of 1-10 employees, Delpor is actively contributing to advancements in Biotechnology. Their latest funding round, Debt Financing - Delpor, raised $470.0K. Discover more about their projects, partnerships, and impact on our platform.